Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole Effect on Regorafenib Bioavailability in mCRC or GIST
NCT02800330Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of regorafenib in metastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), sponsored by Erasmus MC. Started May 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02800330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800330.